METTL4

Across TCGA pan-cancer cohorts, METTL4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated METTL4 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher METTL4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated METTL4 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

SCLC, UCEC, and KIRP are the cancer types where METTL4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.068	0.717	<.001	36	view →
UCEC	DFS	Median	All	1.000	0.626	.008	16	view →
KIRP	OS	Median	II,III,IV	0.188	0.771	.016	12	view →
STAD	OS	Median	All	0.514	0.688	.003	8	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	III,IV	0.235	0.677	.030	3	view →
SKCM	DFS	Median	All	0.954	0.731	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

METTL4–SCLC (OS)

Open the SCLC breakdown →